CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils.
Prion diseases are characterized by conversion of the cellular prion protein (PrP(C)) to a protease-resistant conformer, the srapie form of PrP (PrP(Sc)). Humoral immune responses to nondenatured forms of PrP(Sc) have never been fully characterized. We investigated whether production of antibodies to PrP(Sc) could occur in PrP null (Prnp(-/-)) mice and further, whether innate immune stimulation with the TLR9 agonist CpG oligodeoxynucleotide (ODN) 1826 could enhance this process. Whether such stimulation could raise anti-PrP(Sc) antibody levels in wild-type (Prnp(+/+)) mice was also investigated. Prnp(-/-) and Prnp(+/+) mice were immunized with nondenatured 139A scrapie-associated fibrils (SAF), with or without ODN 1826, and were tested for titers of PrP-specific antibodies. In Prnp(-/-) mice, inclusion of ODN 1826 in the immunization regime increased anti-PrP titers more than 13-fold after two immunizations and induced, among others, antibodies to an N-terminal epitope, which were only present in the immune repertoire of mice receiving ODN 1826. mAb 6D11, derived from such a mouse, reacts with the N-terminal epitope QWNK in native and denatured forms of PrP(Sc) and recombinant PrP and exhibits a K(d) in the 10(-)(11) M range. In Prnp(+/+) mice, ODN 1826 increased anti-PrP levels as much as 84% after a single immunization. Thus, ODN 1826 potentiates adaptive immune responses to PrP(Sc) in 139A SAF-immunized mice. These results represent the first characterization of humoral immune responses to nondenatured, infectious PrP(Sc) and suggest methods for optimizing the generation of mAbs to PrP(Sc), many of which could be used for diagnosis and treatment of prion diseases.
Spinner
Daryl S
DS
New York State Institute for Basic Research in Development Disabilities, 1050 Forest Hill Rd., Staten Island, NY 10314, USA. darylspinner@aol.com
Kascsak
Regina B
RB
Lafauci
Giuseppe
G
Meeker
Harry C
HC
Ye
Xuemin
X
Flory
Michael J
MJ
Kim
Jae Il
JI
Schuller-Levis
Georgia B
GB
Levis
William R
WR
Wisniewski
Thomas
T
Carp
Richard I
RI
Kascsak
Richard J
RJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D000917:Antibody Formation; D004247:DNA / Q000276:immunology*; D000939:Epitopes; D007113:Immunity, Innate; D007114:Immunization; D017578:Immunoglobulin Class Switching; D051379:Mice; D018345:Mice, Knockout; D009838:Oligodeoxyribonucleotides; D018622:PrP 27-30 Protein / Q000276:immunology*; D018620:PrPSc Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000276:immunology
D000911:Antibodies, Monoclonal; C423449:CpG ODN 1826; D000939:Epitopes; D009838:Oligodeoxyribonucleotides; D018620:PrPSc Proteins; C495370:Tlr9 protein, mouse; D051217:Toll-Like Receptor 9; D018622:PrP 27-30 Protein; D004247:DNA